marked.bio

PD-1/CTLA-4 antibody combination · bispecific antibody

iparomlimab and tuvonralimab

11 active trials across 10 of our biomarkers, targeting PD-1 + CTLA-4. Not approved for any biomarker on marked.bio yet.

Also known as QL1706.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 6 6 Phase 3
BRAF V600E 2 2 Phase 2
KRAS G12C 2 2 Phase 2
KRAS G12D 2 2 Phase 1/2
ALK fusion 1 1 Phase 2
Claudin 18.2 expression 1 1 Phase 2
EGFR exon 19 deletion / L858R 1 1 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of iparomlimab and tuvonralimab.

  1. Qilu Pharmaceutical 3

Trials

11 of 11 trials shown

  1. A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

    Recruiting Phase 3 Qilu Pharmaceutical Started 2024Primary completion 2030-12 NCT06686576

    iparomlimab and tuvonralimabcapecitabine

    Has a tumor demonstrating the presence of MSI-H/ dMMR

    MSI-H / dMMRColon Cancer

  2. PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026Primary completion 2027-12 NCT07416058

    iparomlimab and tuvonralimabpemetrexedbevacizumab

    these mutations are stratified as follows: EGFR (19del, L858R)

    EGFR exon 19 deletion / L858RKRAS G12CBRAF V600EHER2 (ERBB2) activating mutationALK fusionROS1 fusionRET fusion or mutationLung Adenocarcinoma

  3. CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2029-12 NCT07383285

    iparomlimab and tuvonralimabcapecitabinebevacizumaboxaliplatin

    The genetic test results were KRAS or NRAS mutations, without BRAF V600 mutations, and the immunohistochemical results were pMMR;

    KRAS G12CKRAS G12DRectal Neoplasms Malignant

  4. Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2028-07 NCT07595523

    iparomlimab and tuvonralimab

    Tumor biopsy demonstrates dMMR status and concurrently meets the criteria for MSI-H.

    MSI-H / dMMRGastric Cancer

  5. Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

    Not yet recruiting Phase 2 Women's Hospital School Of Medicine Zhejiang University Started 2026Primary completion 2027-12 NCT07369986

    iparomlimab and tuvonralimab

    Confirmed dMMR or MSI-H, defined by either loss of expression of one or more mismatch repair proteins (MLH1, PMS2…

    MSI-H / dMMREndometrial Cancer, Immunotherapy, Mismatch Repair Deficiency

  6. A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Not yet recruiting Phase 1/2 Qilu Pharmaceutical Started 2025Primary completion 2026-09 NCT06949761

    QLC1101+QL1203QLC1101+QL2107iparomlimab and tuvonralimabdocetaxel

    Subjects confirmed advanced (metastatic or unresectable) solid tumors with KRAS G12D mutations.

    KRAS G12DSolid Tumor

  7. Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

    Recruiting Phase 2 Sun Yat-sen University Started 2025Primary completion 2027-06 NCT07150247

    iparomlimab and tuvonralimabbevacizumabfluorouracilirinotecan

    BRAF V600E mutation confirmed by tissue pathology or ctDNA testing (PCR or NGS)

    BRAF V600EBRAF V600 Colorectal Cancer

  8. QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

    Not yet recruiting Phase 2 Qianfoshan Hospital Started 2025Primary completion 2026-06 NCT07009145

    iparomlimab and tuvonralimabbevacizumab

    QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

    MSI-H / dMMRUnresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer

  9. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

    Recruiting Phase 2 Peking University Started 2025Primary completion 2027-12 NCT07127822

    iparomlimab and tuvonralimabFirst line chemotherapy plus PD-1/PD-L1 antibody

    Confirmed by PCR or next-generation sequencing(NGS) as microsatellite instability-high(MSI-H) .

    MSI-H / dMMRGastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer

  10. Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Not yet recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2025Primary completion 2028-12 NCT07151209

    iparomlimab and tuvonralimablenvatinib

    …therapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    MSI-H / dMMRGastric or Gastroesophageal Junction Adenocarcinoma

  11. Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

    Not yet recruiting Phase 2 Qilu Pharmaceutical Started 2024Primary completion 2026-06 NCT06446388

    QLS31905oxaliplatincapecitabinegemcitabinecisplatiniparomlimab and tuvonralimabChemotherapy drug

    Tumor tissue samples determined to be positive for Claudin18.2 by immunohistochemistry (IHC);

    Claudin 18.2 expressionStatus may be outdated, last updated 2024-06-06Advanced Solid Tumor